State of the art and perspectives in pediatric hepatocellular carcinoma

Biochemical Pharmacology(2022)

引用 4|浏览8
暂无评分
摘要
Hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC) are rare primary malignant liver cancers in children and young adults. HB is the most common and accounts for about 70 % cases; it is usually diagnosed during the first 3 years of life. Instead, pediatric HCC is uncommon, and it is associated with a poor prognosis. Overall, the prognosis of pediatric HCC is dismal with 5-year event-free survival of <30 % as compared to >80 % for HB.
更多
查看译文
关键词
Hepatocellular carcinoma,Pediatric HCC,Target therapy,Sorafenib,Chemotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要